SCHEMBL4133504

SCHEMBL4133504

Cc1cc(-c2ccc(C(=O)O)c(C(C)C)c2)cc(C)c1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 5/20 0.58
GLRA1 P23415 2/20 0.51
MRGPRX4 Q96LA9 1/20 0.45
CAMKK2 Q96RR4 3/20 0.44
CAMKK1 Q8N5S9 1/20 0.44
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
DHODH Q02127 2/20 0.42
PTGER1 P34995 1/20 0.42
MAPK8 P45983 1/20 0.41
PIK3CG P48736 1/20 0.41
GSK3B P49841 1/20 0.41
MYC P01106 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146025 0.90 MCL1 (0.49) MCL1GLRA1MRGPRX4PDE4APDE4B
SCHEMBL4132651 0.84 MCL1 (0.61) MCL1MRGPRX4PDE4APDE4BPDE4C
SCHEMBL4819103 0.78 MAOB (0.59) MCL1GLRA1MRGPRX4
SCHEMBL10698086 0.78 MCL1 (0.56) MCL1MRGPRX4PPARGPPARADHODH
Lithium Ion SCHEMBL29695998 0.76 MAOB (0.57) MCL1GLRA1MRGPRX4
SCHEMBL128058 0.74 GLRA1 (0.57) GLRA1MRGPRX4PTGER1
SCHEMBL27678664 0.74 PTGER1 (0.51) MCL1GLRA1MRGPRX4PTGER1
SCHEMBL4566984 0.74 MCL1 (0.54) MCL1GLRA1MRGPRX4PTGER1
SCHEMBL12941391 0.74 RXRA (0.51) MCL1GLRA1MRGPRX4PTGER1
SCHEMBL4671597 0.73 ADRB3 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030218-A1 Method For Producing Aminoalcohol Derivative Having Biphenyl Group KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-01-29 US disclosed
US-20090030218-A1 Method For Producing Aminoalcohol Derivative Having Biphenyl Group KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-01-29 US disclosed
US-20090030218-A1 Method For Producing Aminoalcohol Derivative Having Biphenyl Group KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-01-29 US disclosed
EP-1932826-A1 METHOD FOR PRODUCING AMINOALCOHOL DERIVATIVE HAVING BIPHENYL GROUP Kissei Pharmaceutical Co., Ltd. (JP) 2008-06-18 EP disclosed
EP-1932826-A1 METHOD FOR PRODUCING AMINOALCOHOL DERIVATIVE HAVING BIPHENYL GROUP Kissei Pharmaceutical Co., Ltd. (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030218-A1 Method For Producing Aminoalcohol Derivative Having Biphenyl Group ALDH7A1, DDC, ADH5 MCL1 3289/4885GLRA1 4248/4885MRGPRX4 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.